

1 Drivers of ESBL-producing *Escherichia coli* dynamics in calf 2 fattening farms: a modelling study

3 Jonathan Bastard ^{1,2,3,4,5} *, Marisa Haenni ⁶, Emilie Gay ⁷, Philippe Glaser ⁸, Jean-Yves
4 Madec ⁶, Laura Temime ^{3,4}, Lulla Opatowski ^{1,2}

5
6 ¹ Université Paris-Saclay, UVSQ, Univ. Paris-Sud, Inserm, CESP, Anti-infective evasion and
7 pharmacoepidemiology team, F-78180, Montigny-le-Bretonneux, France

8 ² Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion unit, F-75015, Paris,
9 France

10 ³ MESuRS laboratory, Conservatoire national des arts et métiers, 292 rue Saint-Martin, 75003
11 Paris, France

12 ⁴ PACRI unit, Institut Pasteur, Conservatoire national des arts et métiers, Paris, France

13 ⁵ Université Paris Diderot, Sorbonne Paris Cité, Paris, France

14 ⁶ Université de Lyon - Anses, Laboratoire de Lyon, Unité Antibiorésistance et Virulence
15 Bactériennes, Lyon, France

16 ⁷ Université de Lyon - Anses, Laboratoire de Lyon, Unité EAS, Lyon, France

17 ⁸ Ecology and Evolution of Antibiotics Resistance (EERA) unit, CNRS UMR 3525, Institut
18 Pasteur, AP-HP, Université Paris-Sud, Paris, France

19

20 * Corresponding author: jonathan.bastard@pasteur.fr

21 **Abstract**

22 The contribution of bacteria in livestock to the global burden of antimicrobial resistance raises
23 concerns worldwide. However, the dynamics of selection and diffusion of antimicrobial
24 resistance in farm animals are not fully understood. Here, we used veal calf fattening farms as
25 a model system, as they are a known reservoir of Extended Spectrum β -Lactamase-producing
26 *Escherichia coli* (ESBL-EC). Longitudinal data of ESBL-EC carriage and antimicrobial use
27 (AMU) were collected from three veal calf farms during the entire fattening process. We
28 developed 18 agent-based mechanistic models to assess different hypotheses regarding the
29 main drivers of ESBL-EC dynamics in calves. The models were independently fitted to the
30 longitudinal data using Markov Chain Monte Carlo and the best model was selected. Within-
31 farm transmission between individuals and sporadic events of contamination were found to
32 drive ESBL-EC dynamics on farms. In the absence of AMU, the median carriage duration of
33 ESBL-EC was estimated to be 19.6 days (95% credible interval: [12.7; 33.3]). In the best model,
34 AMU was found to influence ESBL-EC dynamics, by affecting ESBL-EC clearance rather than
35 acquisition. This effect of AMU was estimated to decrease gradually after the end of exposure
36 and to disappear after 62.5 days [50.0; 76.9]. Moreover, using a simulation study, we quantified
37 the efficacy of ESBL-EC mitigation strategies. Decreasing ESBL-EC prevalence by 50% on
38 arrival at the fattening farm reduced prevalence at slaughter age by 33.3%. Completely
39 eliminating the use of selective antibiotics had a strong effect on average ESBL-EC prevalence
40 (relative reduction of 79.6%), but the effect was mild if this use was only decreased by 50%
41 compared to baseline (relative reduction of 3.7%).

42

43 **Keywords**

44 Antimicrobial resistance; ESBL; livestock; calves; *Escherichia coli*; mathematical modelling

45 Introduction

46 The detection of antibiotic-resistant bacteria in livestock animals has been a rising concern
47 worldwide [1]. Extended Spectrum β -Lactamase (ESBL)-producing *Enterobacterales*, such as
48 ESBL-producing *E. coli* (ESBL-EC), are a typical example as they are frequently reported in
49 food-producing animals [2], notably calves [3-6]. These bacteria have acquired resistances to
50 most β -lactams and are responsible for severe infections in humans [7]. The importance of
51 considering antimicrobial resistance (AMR), and ESBL-EC in particular, in a One Health
52 perspective is now widely recognized, due to their capability to spread across human, animal
53 and environmental sectors [8, 9].

54 The drivers of AMR spread in livestock are not fully understood, although extensive
55 antimicrobial use (AMU) is assumed to play a major role. Previous studies have investigated
56 the relationship between variations in AMU and AMR in livestock at a scale ranging from an
57 entire country [10-12] to specific farms [13-17], including cattle farms [18-22]. Some of these
58 studies found an association between AMU and AMR, but not all of them. The reason may be
59 that AMR prevalence on a farm not only depends on levels of exposure to antibiotics, but also
60 relies upon several other factors, such as importation of animals colonised with antibiotic-
61 resistant bacteria, within-farm transmission of antibiotic-resistant bacteria between animals
62 and/or from humans, and contamination of animals from the environment. Moreover,
63 antibiotic-resistant bacteria carriage and transmission are dynamic phenomena and may
64 therefore not be well captured by classical statistical models.

65 Mechanistic dynamic models are useful to better understand the spread of AMR in
66 populations [23]. They have been used extensively to study AMR spread in human
67 populations and to assess the effect of control measures [24]. However, dynamic models

68 simulating the transmission of AMR within farms and fitted using real longitudinal data are
69 scarce [25-29].

70 Here, we propose what is, to our knowledge, the first dynamic model of AMR spread among
71 veal calves, informed by longitudinal data on ESBL-EC carriage and AMU. Using this model,
72 we quantitatively assess the efficacy of two different strategies to mitigate ESBL-EC prevalence
73 on farms: decreasing ESBL-EC carriage upon arrival and decreasing AMU on fattening farms.

74

75 **Methods**

76 **Ethics**

77 Animal ethics approval is not required in France for rectal swabbing in calves since this is
78 considered a non-invasive procedure.

79 **Study design and data collection**

80 The field study was led between October 2015 and March 2016 in three veal calf fattening
81 farms located in the Brittany region (France), and referred to as farms A, B and C. As a general
82 scheme in the veal calves industry in France, fattening farms usually rear batches of 250-300
83 dairy calves from 3-5 weeks to 5-6 months of age before slaughter. In accordance with
84 European animal health and welfare directives 91/629/EC and 97/2/EC, calves were kept in
85 individual pens until eight weeks of age, and then gathered in pens housing five calves until
86 their slaughter age. During the fattening cycle, no new calf entered the farm.

87 The study design is described in [30]. In brief, within each participating farm, 50 calves of the
88 same batch were randomly tested on arrival for ESBL-EC carriage. Swabs were streaked on
89 selective ChromID ESBL agar (bioMérieux, Marcy l'Etoile, France) and, on each farm, the 50
90 calves were assigned to a positive or negative ESBL-EC status based on colony growth after 24

91 hours at 37°C. Antimicrobial susceptibility testing was performed using the disc diffusion
92 method and ESBL production was confirmed by the double-disc synergy test. Among these,
93 15 calves per farm were followed longitudinally, resulting in 45 calves in total included in the
94 study. On each farm, calves were allocated to three different pens (five calves per pen) from
95 eight weeks of age, and according to their initial ESBL-EC status. On farms B and C, one pen
96 gathered calves that were all initially ESBL-EC negative, while the other two pens gathered
97 initially ESBL-EC positive calves. On farm A, all three pens gathered ESBL-EC positive calves
98 because all calves tested on this farm were initially ESBL-EC positive (Supplementary Material
99 SM1).

100 On all three farms, rectal swabs were then collected every two weeks from each calf on days
101 7, 21, 35, 49, 63, 77, 91, 106, 119, 133 and 147 after the calves' arrival, plus on day 161 for farms
102 A and B. In total, 180 samples were collected on farms A and B, and 158 samples on farm C
103 (SM1).

104 Over the study period, the antibiotics used were systematically recorded on a daily basis.
105 Antibiotic treatments were independent from calves' ESBL-EC carriage.

106

107 **Dynamic model**

108 To unravel mechanisms underlying the temporal spread of ESBL-EC among calves, we built
109 18 variants of an agent-based discrete-time dynamic stochastic model of ESBL-EC acquisition
110 and transmission within a calf farm. These variants included a various number of mechanisms,
111 as described in Table 1.

112 In the models, at each time step t (day), each calf was classified as either carrier or non-carrier
113 of ESBL-EC. Model parameters are summarized in Table 2 and the full description of the
114 models, including equations, is provided in the SM2. Some parameters were farm-specific,

115 while the others were common to all farms (Table 2). Models were run from day 1 (arrival of
116 calves on the farm) to day 161 (last sampling date).

117 *Initialisation.* The carriage status of each calf on the first day was known from the study design
118 described above.

119 *ESBL-EC acquisition.* At each time t , the probability for an ESBL-EC negative calf to acquire
120 ESBL-EC depended on the model variant (Table 1 and SM2). This acquisition could result
121 either from transmission from other colonised calves, or from sporadic contaminations,
122 depicting the possible acquisition of ESBL-EC by the calves on some specific days (estimated
123 in the models) from another unknown source. Transmission was assumed to occur either
124 homogeneously between calves of the same farm F , with rate β_f^F , or between calves depending
125 on their allocated pen, assuming two transmission rates, within (β_w^F) and between (β_b^F) pens
126 of a farm F . As a null hypothesis, we also investigated models which did not include any
127 transmission between calves, but instead a constant, farm-specific, ESBL-EC acquisition rate
128 β_0^F .

129 *ESBL-EC clearance.* At each time t , the probability for an ESBL-EC positive calf to clear carriage
130 depended on a natural clearance rate, ν_0 , inverse of the baseline carriage duration.

131 *Impact of antibiotics.* Depending on the model variant, AMU was either assumed to have no
132 effect on ESBL-EC dynamics, or to impact the probability of acquisition or clearance. For a
133 given antibiotic class i , its effect on acquisition (resp. clearance) was modelled by a
134 multiplicative factor $a_{a,i}$ (resp. $a_{c,i}$). After the end of exposure, this effect was supposed to persist
135 [31], but decrease exponentially [32] (i.e. tend to 1) with a rate τ , common to all antibiotic
136 classes.

137

138 **Table 1.** Description of the mechanisms included in each model variant. A full mathematical description
139 of the models is given in the SM2.

	Baseline constant acquisition rate	One transmission rate (within farm)	Two transmission rates on farm (within pen and between pens)	Effect of antibiotic exposure on the acquisition rate	Effect of antibiotic exposure on the clearance rate	Sporadic events of contamination
Model 0	X					X
Model 1		X				X
Model 2			X			X
Model 3		X		X		X
Model 4			X	X		X
Model 5		X			X	X
Model 6			X		X	X
Model 7	X			X		X
Model 8	X				X	X
Model 10	X					
Model 11		X				
Model 12			X			
Model 13		X		X		
Model 14			X	X		
Model 15		X			X	
Model 16			X		X	
Model 17	X			X		
Model 18	X				X	

140

141

142

143

144

145

146

147

148

149 **Table 2.** Parameters used in the dynamic models: symbol, description, unit, prior distribution and
 150 whether the parameter was farm specific (i.e. a value was estimated for each farm) or common to all
 151 farms.

Parameter	Description	Unit	Prior distribution	Common or farm-specific
β_0^F	Constant acquisition rate on farm F	(ind.day) ⁻¹	Uniform: [0,10]	Farm specific
β_r^F	Transmission rate within the farm F	(ind.day) ⁻¹	Uniform: [0,10]	Farm specific
β_w^F	Transmission rate within the same pen in farm F	(ind.day) ⁻¹	Uniform: [0,10]	Farm specific
β_b^F	Transmission rate between different pens of the same farm F	(ind.day) ⁻¹	Uniform: [0,10]	Farm specific
ν_0	Baseline clearance rate	day ⁻¹	Uniform: [0,10]	Common
$a_{a,i}$	Effect of exposure to antibiotic of class i on the acquisition of ESBL-EC (for a non-colonised calf)	-	Uniform: [0,10]	Common
$a_{c,i}$	Effect of exposure to antibiotic of class i on the clearance of ESBL-EC (for a colonised calf)	-	Uniform: [0,10]	Common
τ	Rate of decrease of the effect of antibiotics on acquisition or clearance of ESBL-EC after the last day of an exposure event	day ⁻¹	Uniform: [0,1]	Common
N^F	Number of sporadic ESBL-EC contamination events during the production cycle in farm F	-	Categories of equal probabilities: (0, 1, 2)	Farm specific
D^F	Set of dates (days) of occurrence of sporadic contaminations in farm F (N^F elements)	-	Categories of equal probabilities: (8, 9, ..., 161)	Farm specific
μ	Additional acquisition rate due to a sporadic contamination event	(ind.day) ⁻¹	Uniform: [0,10]	Common

152

153

154

155

156

157 **Estimation and model selection**

158 Independently for each of the 18 models, parameters were estimated in a Bayesian framework,
159 using a Markov Chain Monte Carlo (MCMC) algorithm, implemented with the R package *rjags*
160 [33]. Models were fitted to the data from the three farms simultaneously. Non-informative
161 uniform priors were used for all parameters (Table 2). The 18 models were compared using
162 the Deviance Information Criterion (DIC) [34]. Details on modelling assumptions, estimation
163 and validation are provided in the SM3 and SM4.

164 To assess the quality of the best model's fit, we simulated it by sampling parameter values in
165 the estimated posterior distributions, and compared model predictions to observed data in
166 each farm.

167

168 **Simulating changes in farming practices**

169 We ran a simulation study to assess the impact of changes in farming practices on the mean
170 prevalence of ESBL-EC carriage over the fattening cycle and on the final ESBL-EC prevalence
171 at slaughter age, in farm A. We used the best model parameterized with posterior estimates,
172 without sporadic events of contamination.

173 First, we assessed the effect of exposure to “selective” antibiotics during fattening, particularly
174 at the beginning (from day 1), as collective “starting treatments” were a common practice to
175 manage diseases in arriving calves. Here, we defined selective antibiotics as antibiotic classes
176 i for which the estimated value of $a_{a,i}$ (or $a_{c,i}$) was significantly different from 1 in the selected
177 model. The baseline duration of initial exposure to selective antibiotics was defined as six days,
178 based on data from a previous representative study led in 120 French calf fattening farms [35].
179 Then, we simulated reductions in the duration of this initial exposure to assess their effect on
180 ESBL-EC prevalence.

181 Second, we evaluated the effect of ESBL-EC prevalence on arrival at the fattening farm (on day
182 1). We extracted from the literature [21] the baseline value of 68% for this prevalence on arrival
183 in France. We assumed that changes in practices on dairy farms where calves were born could
184 decrease this prevalence on arrival, and simulated such reductions.

185 In all simulations, we differentiated two scenarios. In the first scenario, the only exposure to
186 selective antibiotics was the initial exposure described above. In the second scenario, besides
187 the initial exposure, we simulated a 10-day “mid-cycle exposure” to selective antibiotics
188 between days 81 and 90, to mimic the treatment of diseases during fattening.


189

190 **Results**

191 **ESBL-EC carriage and antimicrobial use over time**

192 ESBL-EC carriage of the 45 calves followed over the fattening cycle is detailed for each
193 sampling date in the SM1. Time changes in the proportion of ESBL-EC positive calves in each
194 farm is depicted in Figure 1. On all three farms, the proportion of ESBL-EC positive calves was
195 higher on the first than on the last sampling day.

196 On each farm, antibiotics were always administered to all calves simultaneously over the
197 study period, i.e. there were no individual treatments. AMU observed on farms is depicted in
198 Figure 1 and described in the SM5.



199

200 *Figure 1. Longitudinal study of ESBL-EC colonisation in three calf fattening farms. Samples*
201 *were collected every two weeks (sampling dates indicated by X) and antibiotic usage was recorded daily*
202 *(period of exposure for the different classes indicated with coloured rectangles). Observed (red*
203 *diamonds), median predicted ESBL-EC prevalence (black line) and 95% prediction interval for each*
204 *farm, using model 5 fitted on the three farms simultaneously (1,000 repetitions of the model), are*
205 *represented.*

206

207 **Parameters estimation and model comparison**

208 Among 18 mechanistic models, model 5, which includes farm-level between-calf transmission,
209 impact of antibiotic exposure on carriage clearance and sporadic contaminations (Table 1)
210 presented the lowest DIC (SM6), and was therefore selected as the best model used for all
211 analyses onwards.

212 The estimated posterior distributions of model 5 parameters are summarized in Table 3 and
213 represented in the SM7. The median posterior baseline clearance rate was 0.051/day,

214 corresponding to a median carriage duration of 19.6 days, in the absence of antibiotic exposure.

215 The median farm-level transmission rate ranged between 0.021 and 0.059 (ind.day)⁻¹,

216 depending on the farm (Table 3).

217 Colistin exposure significantly affected ESBL-EC dynamics: being exposed to colistin on a

218 given day was estimated to multiply the baseline clearance rate on that day by 0.015 (i.e. to

219 divide it by 66.7) in median. Conversely, we did not find that the use of other antibiotic classes

220 modified the baseline clearance: the 95% credibility interval included 1 for parameters $a_{c,Macrolide}$,

221 $a_{c,Penicillin}$, $a_{c,Sulfo.-Trim.}$ and $a_{c,Tetracycline}$. The effect of antibiotic exposure was estimated to decrease

222 over time after the end of an antimicrobial use with a median rate of 0.016/day, suggesting

223 that the antibiotics affected ESBL-EC dynamics up to 62.5 days in median after the end of

224 exposure (Table 3 and SM8).

225 Most (69.3%) and almost all (99.9%) of the posterior samples in farms A and B, respectively,

226 did not include any sporadic contamination. Conversely, there were two in farm C, at the

227 beginning and at the end of the fattening period (Table 3 and SM7).

228 Model 5, estimated on the three farms combined, succeeded in fitting the observed data for

229 each farm, as most of the observed data were in the 95% prediction interval (Figure 1). The fit

230 of model 5 when estimated separately for each farm is shown in the SM9.

231

232

233

234

235

236

237 **Table 3.** Posterior estimates of model 5 parameters: median and 95% highest posterior density interval
 238 (HPDI), or posterior distribution of the categorical variable.

Parameter (unit)	Median of the posterior (95% HPDI) or Posterior distribution of the categorical variable
β_r^A ((ind.day) ⁻¹)	0.021 [0.0034 ; 0.052]
β_r^B ((ind.day) ⁻¹)	0.026 [0.0013 ; 0.061]
β_r^C ((ind.day) ⁻¹)	0.059 [0.030 ; 0.093]
ν_0 (day ⁻¹)	0.051 [0.030 ; 0.079]
$a_{c,Macrolide}$	2.12 [0.60 ; 4.67]
$a_{c,Penicillin}$	2.27 [0.13 ; 7.85]
$a_{c,Colistin}$	0.015 [0.0000026 ; 0.12]
$a_{c,Sulfo.-Trim.}$	0.46 [0.095 ; 1.10]
$a_{c,Tetracycline}$	0.83 [0.17 ; 2.20]
τ (day ⁻¹)	0.016 [0.013 ; 0.020]
μ	6.44 [2.56 ; 9.97]
N^A	0 (69.3%), 1 (22.1%), 2 (8.6%)
N^B	0 (99.9%), 1 (0.1%), 2 (0.0%)
N^C	0 (0.2%), 1 (1.2%), 2 (98.6%)

239

240

241

242

243

244

245 **Impact of changes in farming practices**


246 Figure 2 represents the mean ESBL-EC prevalence over the cycle and ESBL-EC prevalence at
247 slaughter age predicted by model 5 in farm A, when three parameters vary from their baseline
248 values. We varied: (i) ESBL-EC prevalence in calves arriving from dairy farms, (ii) the duration
249 of calves' exposure to selective antibiotics on arrival (from day 1), and (iii) the duration of
250 calves' exposure to selective antibiotics in the middle of the production cycle (two scenarios: 0
251 or 10 days from mid-cycle).

252 In all simulations, both the mean prevalence and prevalence at slaughter age were higher in
253 the scenario with mid-cycle exposure than without. In the baseline situation corresponding to
254 ESBL-EC prevalence on arrival and initial exposure observed in France [21, 35], and assuming
255 a mid-cycle selective antibiotic exposure, the predicted median ESBL-EC prevalence at
256 slaughter age (resp. mean prevalence over the cycle) was 20.0% (resp. 48.9%), which was
257 consistent with the 20.4% observed at slaughter age in [21] (Figure 2). Therefore, in the
258 following, we detail results only for the scenario with mid-cycle exposure, i.e. the most
259 conservative and realistic scenario.

260 If the initial exposure to selective antibiotics was completely eliminated (resp. was reduced
261 from 6 days to 3 days), the mean prevalence over the cycle decreased by a relative 79.6% (resp.
262 3.7%) in median, from 48.9% to 9.96% (resp. 47.1%), and the median prevalence at slaughter
263 age was lowered to 0 (resp. was not affected) (Figure 2B&D).

264 On the other hand, if ESBL-EC prevalence on arrival was cut by half compared to the baseline,
265 from 68% to 34%, the median prevalence at slaughter age (resp. mean prevalence over the
266 cycle) was reduced by a relative 33.3%, from 20.0% to 13.3% (resp. a relative 33.9%, from 48.9%
267 to 32.3%) (Figure 2A&C).

268



269

270 **Figure 2. Simulations of ESBL-EC mitigation strategies.** Mean ESBL-EC prevalence (panels A
 271 and B) and prevalence at slaughter age (panels C and D) predicted by model 5 (1,000 repetitions of the
 272 model), when ESBL-EC prevalence on arrival (panels A and C) and the duration of the initial antibiotic
 273 exposure (panels B and D) are changed from their baseline values. Scenarios without (turquoise) or with
 274 (orange) a 10-day antibiotic exposure in the middle of the fattening cycle (between days 81 and 90) are
 275 explored. Coloured dots are the predicted medians and intervals are 95% prediction intervals. The *
 276 dot is the prevalence at slaughter age observed in [21] and is close to our baseline predictions in the
 277 scenario with a 10-day mid-cycle exposure.

278

279

280 Discussion

281 In this study, using longitudinal data and a dynamic model, we quantitatively estimated the
282 between-calves transmission of ESBL-EC within farms and found a significant and persistent
283 impact of antibiotic exposure on ESBL-EC clearance. From a simulation study, we underlined
284 the potential impact of reductions in antimicrobial use and in ESBL-EC carriage in calves
285 arriving from dairy farms.

286 Consistently with previously reported dynamics in France and the Netherlands [21, 36], ESBL-
287 EC carriage decreased from arrival to departure in all three farms (Figure 1).

288 Depending on the farm, the transmission rate ranged between 0.021 and 0.059 (indiv.day)⁻¹,
289 possibly reflecting differences in farm infrastructure or practices. This is in line with the ESBL-
290 EC transmission rate of 0.06/day estimated in broilers in the Netherlands [28]. Our median
291 estimated carriage duration of 19.6 days was also consistent with previously reported values
292 of 12 days for multidrug-resistant *Salmonella* Typhimurium in dairy cattle [37], and 26.84 days
293 for ESBL-EC in broilers [28].

294 Sporadic contaminations were necessary to reproduce carriage dynamics from farm C. Such
295 unexplained carriage increases were observed before [36]. They may reflect a contamination
296 from the environment, companion animals, humans, or the equipment [22].

297 AMU patterns, with a third of treatments within the first two weeks, half of treatments by
298 tetracycline, and a predominance of collective treatments, were similar to previous studies in
299 French fattening calves [21, 35].

300 In the best model, AMU was shown to affect ESBL-EC clearance, rather than ESBL-EC
301 acquisition. Among five classes of antibiotics used in the farms over the study period, we only
302 detected a significant effect of colistin on ESBL-EC dynamics, maybe due to a lack of power

303 for other antibiotics. For instance, the wide credible interval found for penicillin (Table 3)
304 reflects the fact that this class was hardly used in our study.

305

306 **Main limitations of our study and perspectives**

307 First, we did not account for the diversity in genes conferring the ESBL phenotype and *E. coli*
308 clones. However, robust results can be drawn from modelling phenotypic AMR data alone
309 [38]. Moreover, a mechanistic transmission model fitted with genomic data would need more
310 complexity, accounting for (i) the within-host spread of ESBL genes between *E. coli* clones *via*
311 mobile genetic elements, and (ii) the spread of *E. coli* clones between hosts.

312 Second, we assumed that antibiotic classes had an identical effect on ESBL-EC dynamics in all
313 calves of the three farms, whereas resistance patterns in ESBL-EC strains may present
314 individual variations. Notably, the effect of colistin on ESBL-EC we found may be specific to
315 farm A, with colistin-resistant ESBL-EC selected in this farm only. Further genomic
316 investigations on the presence and possible different distributions of colistin resistance genes
317 in ESBL-EC between farms may help clarify this positive effect of colistin use on ESBL spread.

318

319 **Potential implications of our results for AMR mitigation**

320 We showed how changes in farming practices, resulting from the implementation of AMR
321 mitigation strategies, may impact the ESBL-EC prevalence at slaughter age, reflecting the risk
322 of its spread in the food chain, and its mean prevalence over the fattening cycle. The latter may
323 also be of importance to human health because animals can contaminate their environment
324 and zoonotic transmission to farmers might occur, as observed in other livestock productions
325 [39, 40].

326 Regarding the use of selective antibiotics during fattening, we found a contrast between the
327 strong effect that their complete suppression had on ESBL-EC prevalence, and the mild effect
328 found when their use was only reduced by half (Figure 2). This non-linear effect may be
329 explained by the persistent effect of selective antibiotics on the gut flora [41], even when they
330 are administered for a short duration.

331 Reductions in ESBL-EC prevalence in calves arriving at the fattening farm simulated the
332 hypothetical effect of actions taken at the dairy farm (e.g. reducing AMU in new-born calves
333 or the use of waste milk from treated cows) or transportation levels (e.g. reducing calf-to-calf
334 transmission risk). The impact of such reductions was found to be steadier, as a 50% reduction
335 decreased by a third both the ESBL-EC prevalence at slaughter age and the average ESBL-EC
336 prevalence over the cycle (Figure 2).

337 However, to lead to field application and policy, this assessment would need a more thorough
338 benefit-cost analysis of veterinary, zootechnical and economical features, along different steps
339 of the cattle industry. In particular, calves are administered antibiotics because they are
340 particularly susceptible to various diseases that can affect their growth and cause mortality
341 [42, 43].

342 Moreover, these figures correspond to a situation without sporadic contamination events, that
343 can unexplainably and strongly affect ESBL-EC prevalence on farms, as discussed above. This
344 is why biosecurity is of prime importance when considering measures to mitigate ESBL-EC
345 carriage in calves.

346

347

348

349 **Acknowledgements**

350 We sincerely thank Véronique Métayer for her technical contribution in samples management
351 and antimicrobial susceptibility testing, and Aleksandra Kovacevic for her useful
352 proofreading of the manuscript.

353 **Funding**

354 This work was supported by the INCEPTION project (PIA/ANR-16-CONV-0005) to JB, by
355 internal resources of Institut Pasteur, the French National Institute of Health and Medical
356 Research (Inserm) and the University of Versailles Saint-Quentin-en-Yvelines (UVSQ), by the
357 French Government “Investissement d’Avenir” program Laboratoire d’Excellence
358 “Integrative Biology of Emerging Infectious Diseases” (grant ANR-10-LABX-62-IBEID) and by
359 the European Union’s Horizon 2020 Research and Innovation Programme under Grant
360 Agreement No. 773830 (Project ARDIG, EJP One Health), the TransComp-ESC-R AAP JPI-EC-
361 AMR and INTERBEV (Protocol N° SECU-15-31). The funders had no role in study design, data
362 collection and analysis, decision to publish, or preparation of the manuscript.

363 **Declaration of interest**

364 None to declare.

365

366

367

368

369

370 References

- 371 [1] S.V. Puyvelde, S. Deborggraeve, J. Jacobs. Why the antibiotic resistance crisis requires a
372 One Health approach. *The Lancet Infectious Diseases*. 2017;0(0).
- 373 [2] EFSA, ECDC. The European Union summary report on antimicrobial resistance in zoonotic
374 and indicator bacteria from humans, animals and food in 2016. European Food Safety
375 Authority. 2018.
- 376 [3] J. Dantas Palmeira, H.M.N. Ferreira. Extended-spectrum beta-lactamase (ESBL)-producing
377 Enterobacteriaceae in cattle production – a threat around the world. *Heliyon*. 2020;6(1):e03206.
- 378 [4] M. Haenni, P. Châtre, V. Métayer, M. Bour, E. Signol, J.-Y. Madec, et al. Comparative
379 prevalence and characterization of ESBL-producing Enterobacteriaceae in dominant versus
380 subdominant enteric flora in veal calves at slaughterhouse, France. *Veterinary Microbiology*.
381 2014;171(3):321-7.
- 382 [5] J. Hordijk, J.A. Wagenaar, A. van de Giessen, C. Dierikx, A. van Essen-Zandbergen, K.
383 Veldman, et al. Increasing prevalence and diversity of ESBL/AmpC-type β -lactamase genes
384 in *Escherichia coli* isolated from veal calves from 1997 to 2010. *Journal of Antimicrobial*
385 *Chemotherapy*. 2013;68(9):1970-3.
- 386 [6] H.R. Springer, T.N. Denagamage, G.D. Fenton, B.J. Haley, J.A.S. Van Kessel, E.P. Hovingh.
387 Antimicrobial Resistance in Fecal *Escherichia coli* and *Salmonella enterica* from Dairy Calves:
388 A Systematic Review. *Foodborne Pathog Dis*. 2018;16(1):23-34.
- 389 [7] J.D.D. Pitout, P. Nordmann, K.B. Laupland, L. Poirel. Emergence of Enterobacteriaceae
390 producing extended-spectrum β -lactamases (ESBLs) in the community. *Journal of*
391 *Antimicrobial Chemotherapy*. 2005;56(1):52-9.
- 392 [8] S. Hernando-Amado, T.M. Coque, F. Baquero, J.L. Martínez. Defining and combating
393 antibiotic resistance from One Health and Global Health perspectives. *Nature Microbiology*.
394 2019;4(9):1432-42.
- 395 [9] J.Y. Madec, M. Haenni, P. Nordmann, L. Poirel. Extended-spectrum β -lactamase/AmpC-
396 and carbapenemase-producing Enterobacteriaceae in animals: a threat for humans? *Clinical*
397 *Microbiology and Infection*. 2017;23(11):826-33.
- 398 [10] F.M. Aarestrup, H. Kruse, E. Tast, A.M. Hammerum, L.B. Jensen. Associations Between
399 the Use of Antimicrobial Agents for Growth Promotion and the Occurrence of Resistance
400 among *Enterococcus faecium* from Broilers and Pigs in Denmark, Finland, and Norway.
401 *Microbial Drug Resistance*. 2000;6(1):63-70.
- 402 [11] B. Callens, M. Cargnel, S. Sarrazin, J. Dewulf, B. Hoet, K. Vermeersch, et al. Associations
403 between a decreased veterinary antimicrobial use and resistance in commensal *Escherichia*
404 *coli* from Belgian livestock species (2011–2015). *Prev Vet Med*. 2018;157:50-8.
- 405 [12] L. Dutil, R. Irwin, R. Finley, L.K. Ng, B. Avery, P. Boerlin, et al. Ceftiofur resistance in
406 *Salmonella enterica* serovar Heidelberg from chicken meat and humans, Canada. *Emerg Infect*
407 *Dis*. 2010;16(1):48-54.
- 408 [13] V.D. Andersen, D.K. LV, P. Munk, M.S. Jensen, Y. Agerso, F.M. Aarestrup, et al. The
409 association between measurements of antimicrobial use and resistance in the faeces microbiota
410 of finisher batches. 2017(1469-4409 (Electronic)).
- 411 [14] J. Kylie, S.A. McEwen, P. Boerlin, R.J. Reid-Smith, J.S. Weese, P.V. Turner. Prevalence of
412 antimicrobial resistance in fecal *Escherichia coli* and *Salmonella enterica* in Canadian
413 commercial meat, companion, laboratory, and shelter rabbits (*Oryctolagus cuniculus*) and its
414 association with routine antimicrobial use in commercial meat rabbits. *Prev Vet Med*.
415 2017;147:53-7.
- 416 [15] N.T. Nguyen, H.M. Nguyen, C.V. Nguyen, T.V. Nguyen, M.T. Nguyen, H.Q. Thai, et al.
417 Use of Colistin and Other Critical Antimicrobials on Pig and Chicken Farms in Southern

- 418 Vietnam and Its Association with Resistance in Commensal *Escherichia coli* Bacteria. *Appl*
419 *Environ Microbiol.* 2016;82(13):3727-35.
- 420 [16] K.L. Tang, N.P. Caffrey, D.B. Nóbrega, S.C. Cork, P.E. Ronksley, H.W. Barkema, et al.
421 Restricting the use of antibiotics in food-producing animals and its associations with antibiotic
422 resistance in food-producing animals and human beings: a systematic review and meta-
423 analysis. *The Lancet Planetary Health.* 2017;1(8):e316-e27.
- 424 [17] C. Varga, A. Rajić, M.E. McFall, R.J. Reid-Smith, S.A. McEwen. Associations Among
425 Antimicrobial Use and Antimicrobial Resistance of *Salmonella* spp. Isolates from 60 Alberta
426 Finishing Swine Farms. *Foodborne Pathog Dis.* 2008;6(1):23-31.
- 427 [18] A.C.B. Berge, D.A. Moore, W.M. Sisco. Field Trial Evaluating the Influence of
428 Prophylactic and Therapeutic Antimicrobial Administration on Antimicrobial Resistance of
429 Fecal *Escherichia coli* in Dairy Calves. *Appl Environ Microbiol.* 2006;72(6):3872.
- 430 [19] B. Catry, J. Dewulf, D. Maes, B. Pardon, B. Callens, M. Vanrobaeys, et al. Effect of
431 Antimicrobial Consumption and Production Type on Antibacterial Resistance in the Bovine
432 Respiratory and Digestive Tract. *PLOS ONE.* 2016;11(1):e0146488.
- 433 [20] S.L. Checkley, J.R. Campbell, M. Chirino-Trejo, E.D. Janzen, C.L. Waldner. Associations
434 between antimicrobial use and the prevalence of antimicrobial resistance in fecal *Escherichia*
435 *coli* from feedlot cattle in western Canada. *The Canadian veterinary journal = La revue*
436 *veterinaire canadienne.* 2010;51(8):853-61.
- 437 [21] E. Gay, M. Bour, G. Cazeau, N. Jarrige, C. Martineau, J.-Y. Madec, et al. Antimicrobial
438 Usages and Antimicrobial Resistance in Commensal *Escherichia coli* From Veal Calves in
439 France: Evolution During the Fattening Process. 2019;10(792).
- 440 [22] J. Hordijk, E.A.J. Fischer, T. van Werven, S. Sietsma, L. Van Gompel, A.J. Timmerman, et
441 al. Dynamics of faecal shedding of ESBL- or AmpC-producing *Escherichia coli* on dairy farms.
442 *J Antimicrob Chemother.* 2019;74(6):1531-8.
- 443 [23] G.M. Knight, N.G. Davies, C. Colijn, F. Coll, T. Donker, D.R. Gifford, et al. Mathematical
444 modelling for antibiotic resistance control policy: do we know enough? *BMC Infect Dis.*
445 2019;19(1):1011.
- 446 [24] L. Opatowski, D. Guillemot, P.-Y. Boëlle, L. Temime. Contribution of mathematical
447 modeling to the fight against bacterial antibiotic resistance. *Curr Opin Infect Dis.* 2011;24(3).
- 448 [25] M. Andraud, N. Rose, M. Laurentie, P. Sanders, A. Le Roux, R. Cariolet, et al. Estimation
449 of transmission parameters of a fluoroquinolone-resistant *Escherichia coli* strain between pigs
450 in experimental conditions. *Veterinary research.* 2011;42(1):44-.
- 451 [26] E.M. Broens, C. Espinosa-Gongora, E.A.M. Graat, N. Vendrig, P.J. Van Der Wolf, L.
452 Guardabassi, et al. Longitudinal study on transmission of MRSA CC398 within pig herds.
453 *BMC Veterinary Research.* 2012;8:58.
- 454 [27] E.M. Broens, E.A.M. Graat, A.W. van de Giessen, M.J. Broekhuizen-Stins, M.C.M. de Jong.
455 Quantification of transmission of livestock-associated methicillin resistant *Staphylococcus*
456 *aureus* in pigs. *Veterinary Microbiology.* 2012;155(2-4):381-8.
- 457 [28] P.M.C. Huijbers, E.A.M. Graat, A.H.A.M. van Hoek, C. Veenman, M.C.M. de Jong, E. van
458 Duijkeren. Transmission dynamics of extended-spectrum β -lactamase and AmpC β -
459 lactamase-producing *Escherichia coli* in a broiler flock without antibiotic use. *Prev Vet Med.*
460 2016;131:12-9.
- 461 [29] G. Mourand, M. Andraud, E. Jouy, C. Chauvin, L. Le Devendec, F. Paboeuf, et al. Impact
462 of colistin administered before or after inoculation on the transmission of a *mcr-1* colistin-
463 resistant *Escherichia coli* strain between pigs. *Veterinary Microbiology.* 2019;230:164-70.
- 464 [30] M. Massot, M. Haenni, T.T. Nguyen, J.-Y. Madec, F. Mentré, E. Denamur. Temporal
465 dynamics of the fecal microbiota in veal calves in a 6-month field trial. Preprint available at
466 Research Square: <https://doi.org/10.21203/rs.3.rs-22572/v1>. 2020.

- 467 [31] S. Caballero, S. Kim, R.A. Carter, I.M. Leiner, B. Sušac, L. Miller, et al. Cooperating
468 Commensals Restore Colonization Resistance to Vancomycin-Resistant *Enterococcus faecium*.
469 *Cell Host Microbe*. 2017;21(5):592-602.e4.
- 470 [32] E.N. Abatih, L. Alban, A.K. Ersbøll, D.M. Lo Fo Wong. Impact of antimicrobial usage on
471 the transmission dynamics of antimicrobial resistant bacteria among pigs. *Journal of*
472 *Theoretical Biology*. 2009;256(4):561-73.
- 473 [33] M. Plummer, A. Stukalov, M. Denwood, M.M. Plummer. Package 'rjags'. 2018.
- 474 [34] D.J. Spiegelhalter, N.G. Best, B.P. Carlin, A.J.J.o.t.R.S.S.S.B. Van Der Linde. Bayesian
475 measures of model complexity and fit. 2002;64(4):583-639.
- 476 [35] N. Jarrige, G. Cazeau, E. Morignat, M. Chantepedrix, E. Gay. Quantitative and qualitative
477 analysis of antimicrobial usage in white veal calves in France. *Prev Vet Med*. 2017;144:158-66.
- 478 [36] J. Hordijk, D.J. Mevius, A. Kant, M.E.H. Bos, H. Graveland, A.B. Bosman, et al. Within-
479 farm dynamics of ESBL/AmpC-producing *Escherichia coli* in veal calves: a longitudinal
480 approach. *Journal of Antimicrobial Chemotherapy*. 2013;68(11):2468-76.
- 481 [37] C. Lanzas, L.D. Warnick, K.L. James, E.M. Wright, M. Wiedmann, Y.T. Gröhn.
482 Transmission Dynamics of a Multidrug-Resistant *Salmonella Typhimurium* Outbreak in a
483 Dairy Farm. *Foodborne Pathog Dis*. 2010;7(4):467-74.
- 484 [38] Y.T. Grohn, C. Carson, C. Lanzas, L. Pullum, M. Stanhope, V. Volkova. A proposed
485 analytic framework for determining the impact of an antimicrobial resistance intervention.
486 *Anim Health Res Rev*. 2017;18(1):1-25.
- 487 [39] C. Dierikx, J. van der Goot, T. Fabri, A. van Essen-Zandbergen, H. Smith, D. Mevius.
488 Extended-spectrum- β -lactamase- and AmpC- β -lactamase-producing *Escherichia coli* in Dutch
489 broilers and broiler farmers. *Journal of Antimicrobial Chemotherapy*. 2012;68(1):60-7.
- 490 [40] W. Dohmen, M.J.M. Bonten, M.E.H. Bos, S. van Marm, J. Scharringa, J.A. Wagenaar, et al.
491 Carriage of extended-spectrum beta-lactamases in pig farmers is associated with occurrence
492 in pigs. *Clinical Microbiology and Infection*. 2015;21(10):917-23.
- 493 [41] T. Looft, H.K. Allen. Collateral effects of antibiotics on mammalian gut microbiomes. *Gut*
494 *Microbes*. 2012;3(5):463-7.
- 495 [42] C. Bähler, A. Steiner, A. Luginbühl, A. Ewy, H. Posthaus, D. Strabel, et al. Risk factors for
496 death and unwanted early slaughter in Swiss veal calves kept at a specific animal welfare
497 standard. *Research in Veterinary Science*. 2012;92(1):162-8.
- 498 [43] B. Pardon, K. De Blecker, M. Hostens, J. Callens, J. Dewulf, P. Deprez. Longitudinal study
499 on morbidity and mortality in white veal calves in Belgium. *BMC Veterinary Research*.
500 2012;8:26-.

501

502